Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

Original languageEnglish (US)
Pages (from-to)1551-1558
Number of pages8
JournalBlood
Volume127
Issue number12
DOIs
StatePublished - Mar 24 2016

Fingerprint

Daunorubicin
Cytogenetics
Radiology
Oncology
Hazards
Imaging techniques
Survival
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Luskin, M. R., Lee, J. W., Fernandez, H. F., Abdel-Wahab, O., Bennett, J. M., Ketterling, R. P., ... Luger, S. M. (2016). Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 127(12), 1551-1558. https://doi.org/10.1182/blood-2015-07-657403

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. / Luskin, Marlise R.; Lee, Ju Whei; Fernandez, Hugo F.; Abdel-Wahab, Omar; Bennett, John M.; Ketterling, Rhett P.; Lazarus, Hillard M.; Levine, Ross L.; Litzow, Mark R; Paietta, Elisabeth M.; Patel, Jay P.; Racevskis, Janis; Rowe, Jacob M.; Tallman, Martin S.; Sun, Zhuoxin; Luger, Selina M.

In: Blood, Vol. 127, No. 12, 24.03.2016, p. 1551-1558.

Research output: Contribution to journalArticle

Luskin, MR, Lee, JW, Fernandez, HF, Abdel-Wahab, O, Bennett, JM, Ketterling, RP, Lazarus, HM, Levine, RL, Litzow, MR, Paietta, EM, Patel, JP, Racevskis, J, Rowe, JM, Tallman, MS, Sun, Z & Luger, SM 2016, 'Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups', Blood, vol. 127, no. 12, pp. 1551-1558. https://doi.org/10.1182/blood-2015-07-657403
Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-1558. https://doi.org/10.1182/blood-2015-07-657403
Luskin, Marlise R. ; Lee, Ju Whei ; Fernandez, Hugo F. ; Abdel-Wahab, Omar ; Bennett, John M. ; Ketterling, Rhett P. ; Lazarus, Hillard M. ; Levine, Ross L. ; Litzow, Mark R ; Paietta, Elisabeth M. ; Patel, Jay P. ; Racevskis, Janis ; Rowe, Jacob M. ; Tallman, Martin S. ; Sun, Zhuoxin ; Luger, Selina M. / Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. In: Blood. 2016 ; Vol. 127, No. 12. pp. 1551-1558.
@article{b3e7f363d3e74d0a9089d6da4393970a,
title = "Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups",
abstract = "The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (",
author = "Luskin, {Marlise R.} and Lee, {Ju Whei} and Fernandez, {Hugo F.} and Omar Abdel-Wahab and Bennett, {John M.} and Ketterling, {Rhett P.} and Lazarus, {Hillard M.} and Levine, {Ross L.} and Litzow, {Mark R} and Paietta, {Elisabeth M.} and Patel, {Jay P.} and Janis Racevskis and Rowe, {Jacob M.} and Tallman, {Martin S.} and Zhuoxin Sun and Luger, {Selina M.}",
year = "2016",
month = "3",
day = "24",
doi = "10.1182/blood-2015-07-657403",
language = "English (US)",
volume = "127",
pages = "1551--1558",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

AU - Luskin, Marlise R.

AU - Lee, Ju Whei

AU - Fernandez, Hugo F.

AU - Abdel-Wahab, Omar

AU - Bennett, John M.

AU - Ketterling, Rhett P.

AU - Lazarus, Hillard M.

AU - Levine, Ross L.

AU - Litzow, Mark R

AU - Paietta, Elisabeth M.

AU - Patel, Jay P.

AU - Racevskis, Janis

AU - Rowe, Jacob M.

AU - Tallman, Martin S.

AU - Sun, Zhuoxin

AU - Luger, Selina M.

PY - 2016/3/24

Y1 - 2016/3/24

N2 - The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

AB - The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

UR - http://www.scopus.com/inward/record.url?scp=84962304176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962304176&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-07-657403

DO - 10.1182/blood-2015-07-657403

M3 - Article

C2 - 26755712

AN - SCOPUS:84962304176

VL - 127

SP - 1551

EP - 1558

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -